A Randomized Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With MK-1775 in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers

Trial Profile

A Randomized Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With MK-1775 in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers

Suspended
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs AZD-1775 (Primary) ; Gemcitabine (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Aug 2017 Status changed from recruiting to suspended for interim monitoring.
    • 03 Aug 2017 Status changed from recruiting to suspended for interim monitoring.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top